CPI-200 is under clinical development by Coordination Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CPI-200’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CPI-200 overview

CPI-200 is under development for the treatment of solid tumor. It is administered as intravenous infusion. It is developed based on nanoscale coordination polymer (NCP) platform technology.

Coordination Pharmaceuticals overview

Coordination Pharmaceuticals, Inc., an immune-oncology company commercializing the nanoscale coordination polymer (NCP) technology for immunotherapy of recurrent and metastatic solid tumors. The company is headquartered in United States.

For a complete picture of CPI-200’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.